^
    Back
    Association details:
    Biomarker:TNFRSF8 positive
    Cancer:Peripheral T-cell Lymphoma
    Drug:Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/22/2021
    Excerpt:
    Peripheral T-Cell Lymphomas...Preferred regimen...Brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, and prednisone)...Brentuximab vedotin and bendamustine for CD30+ PTCL...
    Secondary therapy:
    CHP; bendamustine
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASH 2021
    Title:

    The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

    Published date:
    11/04/2021
    Excerpt:
    Eligible pts with previously untreated CD30+ PTCL were randomized 1:1 to A+CHP or CHOP for 6 or 8 cycles….OS was also longer in the A+CHP arm (HR 0.66 [95% CI: 0.43, 1.01], P=0.0529) overall and across IPI subgroups: 0-1 (HR 0.73 [95% CI: 0.20, 2.73], P=0.6411), 2-3 (HR 0.57 [95% CI: 0.32, 1.01], P=0.0496), and 4-5 (HR 0.89 [95% CI: 0.42, 1.89], P=0.7606)....ECHELON-2 results at 5 years demonstrate a generally consistent benefit of A+CHP over CHOP across subgroups and for the ITT population.
    Secondary therapy:
    CHP
    DOI:
    10.1182/blood-2021-145124
    Trial ID:
    ECHELON-2
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Ann Oncol
    Title:

    The ECHELON-2 Trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

    Excerpt:
    In this 5-year update of ECHELON-2, frontline treatment of patients with PTCL with A+CHP continues to provide clinically meaningful improvement in PFS and OS vs CHOP, with a manageable safety profile, including continued resolution or improvement of PN.
    Secondary therapy:
    CHP
    DOI:
    10.1016/j.annonc.2021.12.002
    Trial ID:
    ECHELON-2
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Hodgkin Lymphoma)
    New
    Title:

    European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

    Excerpt:
    Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas

    Excerpt:
    ...Criteria of positive CD30 expression are defined as in cases with membranous CD30 expression from more than 50% of neoplastic cells....
    Trial ID:
    BRAN
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

    Excerpt:
    ...- Patients with histologically proven, CD30 positive (at least 5% of cells according to local examination) peripheral T-cell lymphoma (PTCL) according to the 2016 World Health Organization (WHO) classification for whom gemcitabine treatment is expected....
    Trial ID:
    TOTAL
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

    Excerpt:
    ...Maximum tolerated dose, dose-limiting toxicities of the combination therapy, and recommended phase 2 dose, in patients with relapsed/refractory cutaneous T-cell lymphoma, CD30-positive Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma. ...
    Trial ID:
    EpiBrentlen
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

    Excerpt:
    ...- Patients with newly diagnosed, CD30-positive mature T-cell lymphomas...
    Trial ID:
    ECHELON-2
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

    Excerpt:
    ...Positive CD30 expression by local pathology assessment....
    Trial ID:
    PTCL-CHEPA
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    The standard of care for patients with newly diagnosed CD30-positive PTCL is treatment with a combination of drugs called CHOP. This study is conducted to improve the effectiveness of CHOP chemotherapy with combination therapy, in which vincristine is replaced by brentuximab vedotin. Also, the addition of etoposide to various chemotherapy regimens for T-lymphomas has been associated with promising results in several other studies. This combination is called A + CHEP. Standardem péče pro pacienty s nově zjištěným CD30 pozitivním PTCL je léčba kombinací léků zvaných CHOP. Tato studie se provádí s cílem zlepšit účinnost chemoterapie CHOP s kombinovanou léčbou, v níž se vinkristin nahradí přípravkem brentuximab vedotin. Taktéž přidání etoposidu do různých režimů chemoterapie u T-lymfomů bylo v několika dalších studiích spojeno se slibnými výsledky. Tato kombinace se nazývá A+CHEP [brentuximab vedotin plus cyklofosfamid, doxorubicin, etoposid, prednison].

    Excerpt:
    ...Positive CD30 expression by local pathology assessment. ...
    Trial ID:
    2021-003526-80
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

    Excerpt:
    ...- CD30-positivity (e.g....
    Trial ID:
    P30CA033572
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

    Excerpt:
    ...CD30-positive participants....
    Trial ID:
    NCT04213209
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

    Excerpt:
    ...- Participants with CD30 positive mature T- cell lymphomas who have received A-CHP as induction and achieved complete response (CR) or chemo- sensitive partial response (PR) and deemed suitable for ASCT as consolidation....
    Trial ID:
    BRENTICON-T
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2023
    Title:

    BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS: REAL-WORLD DATA

    Published date:
    06/09/2023
    Excerpt:
    ...we identified patients (pts) ≥ 18 years of age with histologically confirmed CD30+ PTCL (diagnosed between August 2020 to October 2022), who received BV in combination with chemotherapy as 1st line treatment….The overall objective response rate (ORR) was 80% with 63% complete response (CR)....The median follow-up of surviving pts is 16.6 months (range; 4.3- 31.3). The overall 18-months PFS and OS probability were 61.8% and 73.7%, respectively (Figure 1).
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1002/hon.3165_609
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2023
    Title:

    Safety and efficacy of brentuximab vedotin in Chinese adults with CD30+ peripheral T-cell lymphoma: an interim analysis from a prospective, observational, real-world study

    Published date:
    06/09/2023
    Excerpt:
    ...pts in R/R settings (R/R pts received more than 10 BV-based regimens like BV + Chemo, BV + Chemo + Chidamide, BV + Chemo + PD-1 inhibitors)… In R/R settings, ORR was 71.4% (5/7) with CR in 2 (28.6%) and PR in 3 (42.9%) pts. The median time to PR was 2 months...BV-based treatment regimens are safe and effective options in frontline and R/R settings in CD30+ PTCL pts.
    Secondary therapy:
    Chemotherapy + PD1 inhibitor; Chemotherapy; Chemotherapy + chidamide
    DOI:
    10.1002/hon.3164_376
    Trial ID:
    NCT04837222
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    956 Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”

    Published date:
    11/03/2022
    Excerpt:
    Patients with confirmed CD30+ (≥5%) PTCL with measurable disease who failed or were refractory to 1-3 systemic therapy (excluding G and Bv) and ECOG performance status < 3 were eligible….the addition of Bv to G is active in R/R CD30+ PTCLs both in terms of ORR, CR.
    Secondary therapy:
    gemcitabine
    DOI:
    https://doi.org/10.1182/blood-2022-165217
    Trial ID:
    TOTAL
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

    Published date:
    11/04/2021
    Excerpt:
    From February 2019 to April 2021, 21 patients with de novo newly diagnosed CD30+ PTCL have been treated with the combination of BV-CHP....Of the 18 evaluable patients, the overall response rate (ORR) was of 83%, with 72% complete responses and 11% partial responses....Brentuximab Vedotin plus CHP is an effective regimen for CD30 positive PTCL, with a high rate of response.
    Secondary therapy:
    CHP
    DOI:
    10.1182/blood-2021-149506